Lenvatinib and Pembrolizumab Move the Needle for Most Non–clear-cell Renal Cell Carcinomas, Yet Rare Histologies Still Lag Behind

IF 25.2 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-09-15 DOI:10.1016/j.eururo.2025.08.009

Nazli Dizman, Hedyeh Ebrahimi, Alexander Chehrazi-Raffle

引用次数: 0

Abstract

No Abstract

查看原文本刊更多论文

Lenvatinib和Pembrolizumab在大多数非透明细胞肾细胞癌的治疗中发挥了作用，但罕见的组织学仍然落后

没有抽象的

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.